A. Chimalakonda, “Selective Inhibition of Tyrosine Kinase 2 With Deucravacitinib (BMS-986165) Compared With Janus Kinase 1−3 Inhibitors”, J of Skin, vol. 4, no. 6, p. s108, Oct. 2020.